1202357-66-1

Basic information

• Product Name: 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester
• Synonyms: 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester;ethyl 2-[(6-chloro-2-methylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxylate
• CAS NO: 1202357-66-1
• Molecular Formula: C₁₁H₁₁ClN₄O₂S
• Molecular Weight: 298.75
• Mol File: 1202357-66-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester(1202357-66-1)
• EPA Substance Registry System: 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester(1202357-66-1)

Safety Data

• Hazardous Substances Data: 1202357-66-1(Hazardous Substances Data)

Usage

Chemical structure

2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester consists of a thiazole ring and a pyrimidine ring, with a carboxylic acid and ethyl ester groups attached.

Potential applications

The compound has potential pharmaceutical applications, particularly in the development of new drugs for antiviral and antibacterial purposes.

Biological activity

The presence of chloro and methyl substituents on the pyrimidine ring may contribute to the compound's biological activity, affecting its interaction with biological systems.

Medicinal chemistry research

The compound is likely to be used in medicinal chemistry research to study its biological and pharmacological properties, which may lead to the development of effective drugs.

Further studies

Additional research may be needed to fully understand the properties and potential applications of 2-(6-Chloro-2-methylpyrimidin-4-ylamino)thiazole-5-carboxylic acid ethyl ester in the context of drug development.

Upstream product

• 1780-26-3 2,4-dichloro-2-methylpyrimidine 
• 32955-21-8 2-amino-thiazole-5-carboxylic acid ethyl ester 

Downstream Products

• 1497436-07-3 (2E)-N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxamide 
• 1497436-11-9 (2E)-N-(2-chloro-6-methylphenyl)-3-(4-methoxybenzyl)-2-[(2-methyl-6-piperazin-1-ylpyrimidin-4-yl)imino]-2,3-dihydro-1,3-thiazole-5-carboxamide 
• 1497436-15-3 C₃₀H₃₀⁽²⁾H₄ClN₇O₃S 
• 1497436-18-6 C₄₁H₄₉⁽²⁾H₄ClN₈O₆S 
• 1497436-02-8 (2E)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxylic acid 
• 1497435-99-0 ethyl (2E)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxylate 
• 302964-08-5 2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide 
• 302962-49-8 dasatanib 
• 903564-48-7 2-{6-[4-(2-hydroxyethyl)-piperazin-1-yl]-2-methylpyrimidin-4-ylamino}-thiazole-5-carboxylic acid [2-methyl-5-(3-trifluoromethylbenzoylamino)-phenyl]-amide 

Relevant articles and documents

HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family CSF1R, ABL/BCR-ABL, SRC, HCK, PDGFR, KIT and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention are distinctive; possessing a particular class of halogenated heteroaryls. Such kinase inhibitors can display one or more certain properties distinct to dasatinib and other structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally similar kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions disclosed herein may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.

HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF

The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitors of the invention can display one or more certain properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise one or more of the kinase inhibitors. The kinase inhibitors or pharmaceutical compositions of the invention may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. The kinase inhibitors or pharmaceutical compositions may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.

INTRACELLULAR KINASE ASSOCIATED WITH RESISTANCE AGAINST ANTI-TUMOUR IMMUNE RESPONSES, AND USES THEREOF

The invention is based on the surprising finding that SIK3 is associated with resistance against anti-tumour immune responses. In particular, the invention provides methods for treating proliferative diseases using inhibitors of SIK3, especially nucleic acid or small molecule inhibitors of SIK3. Also provided are methods of sensitising cells involved with a proliferative disorder against the cytotoxic effect of certain pro-inflammatory signalling pathways, and/or to kill such cells and/or methods for treating proliferative diseases, using a SIK3 inhibitor together with ligands or agonists of such signalling pathways. Other methods provided by the invention include those involving SIK3 inhibitors to enhance or overcome certain side effects associated with treatments that utilise such signalling pathways, as well as diagnostic, prognostic and monitoring methods and kits based on the detection of SIK3 in a sample obtained from a subject, and screening methods useful for identifying or characterising inhibitors of SIK3.

Design and synthesis of novel dasatinib derivatives as inhibitors of leukemia stem cells

We used the concept of bioisosteres to design and synthesize a novel series of dasatinib derivatives for the treatment of leukemia. Unfortunately, most of the dasatinib derivatives did not show appreciable inhibition against leukemia cell lines K562 and H

DUAL SRC/P38 KINASE INHIBITOR COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

Dual Src/p38 kinase inhibitor compounds and compositions comprising the same are disclosed. Methods of using the compounds in the treatment of hyperproliferative disease such as cancer are also disclosed.

Synthesis and biopharmaceutical studies of jltn as potential dasatinib prodrug

Dasatinib was identified as a potent orally administered Src/Abl kinase inhibitor with excellent antiproliferative activity against Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. The low bioavailability of Dasatinib may be due to both incomplete oral absorption and first-pass metabolism. A prodrug, JLTN, was synthesized to minimize the first-pass effect of Dasatinib and improve the oral bioavailability following oral administration via targeting intestinal peptide transporter and enhancing chemical stability. Biological evaluation data indicated that there was a 150%-fold increase in oral bioavailability of this prodrug compared to the parent drug Dasatinib in monkeys.